To the Editor In the recent article by Guo et al,1 the authors report outcomes of 4 age-defined cohorts receiving antileukemia drugs and a microtransplant. There are no controls not receiving a microtransplant, so it is impossible to know what impact the microtransplant, if any, had on the reported outcomes. Moreover, there is no attempt to account for obvious selection biases operating in the older subject cohorts. An explanation seems warranted.
Gale RP. Study Limitations in HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia. JAMA Oncol. 2018;4(6):891. doi:10.1001/jamaoncol.2018.0364
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: